Literature DB >> 15068697

Analysis of fetal blood cells in the maternal circulation: challenges, ongoing efforts, and potential solutions.

Esther Guetta1, Michal J Simchen, Keren Mammon-Daviko, Daphna Gordon, Ayala Aviram-Goldring, Nurit Rauchbach, Gad Barkai.   

Abstract

The invasive procedures amniocentesis and chorionic villus sampling (CVS) are routinely applied in pregnancies at risk for fetal abnormalities and the results obtained are the gold standard for prenatal diagnosis. Because these methods of fetal cell procurement involve a 0.5-2% risk for fetal loss, they are recommended mainly in cases at high risk for fetal genetic or cytogenetic abnormalities. The development of a reproducible, reliable, noninvasive method based on retrieval of rare fetal cells from the maternal circulation will render testing feasible for the general population. Despite intensive investigation, a satisfactory, clinically acceptable method has not yet emerged. Several cell types have been targeted to this end, mostly nucleated red blood cells (NRBC), CD34+ hematopoietic progenitors, and trophoblasts. Although these cell types have been unequivocally proven to be present in the maternal circulation, each bears a significant disadvantage, rendering their application in clinical testing currently impossible: NRBC cannot be expanded in culture, thereby ruling out metaphase chromosome analysis, an essential component of prenatal diagnosis. CD34+ cells do posses the potential for in vitro proliferation, however, they have been found to persist in the maternal circulation after delivery, thereby complicating diagnosis in consecutive pregnancies. Trophoblasts are not consistently detected in the maternal circulation. Moreover, due to the lack of a definitive fetal cell marker and a reliable sorting method, foolproof fetal cell identification of any of these cell types is not possible. This report outlines the obstacles that impede development of a method for noninvasive fetal cell sampling for prenatal genetic diagnosis, along with a description of our efforts to analyze simultaneously two fetal blood cell types, NRBC and CD34+ cells in maternal blood during pregnancy, and the problems encountered. This work and that of others lead us to suggest potential future directions to help develop this important technique.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068697     DOI: 10.1089/154732804773099290

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  5 in total

Review 1.  Noninvasive prenatal testing: the future is now.

Authors:  Errol R Norwitz; Brynn Levy
Journal:  Rev Obstet Gynecol       Date:  2013

Review 2.  Microfluidic blood cell sorting: now and beyond.

Authors:  Zeta Tak For Yu; Koh Meng Aw Yong; Jianping Fu
Journal:  Small       Date:  2014-02-10       Impact factor: 13.281

3.  Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci.

Authors:  Bernhard Zimmermann; Matthew Hill; George Gemelos; Zachary Demko; Milena Banjevic; Johan Baner; Allison Ryan; Styrmir Sigurjonsson; Nikhil Chopra; Michael Dodd; Brynn Levy; Matthew Rabinowitz
Journal:  Prenat Diagn       Date:  2012-10-30       Impact factor: 3.050

4.  Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy.

Authors:  Andrew B Sparks; Eric T Wang; Craig A Struble; Wade Barrett; Renee Stokowski; Celeste McBride; Jacob Zahn; Kevin Lee; Naiping Shen; Jigna Doshi; Michel Sun; Jill Garrison; Jay Sandler; Desiree Hollemon; Patrick Pattee; Aoy Tomita-Mitchell; Michael Mitchell; John Stuelpnagel; Ken Song; Arnold Oliphant
Journal:  Prenat Diagn       Date:  2012-01-06       Impact factor: 3.050

5.  Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ).

Authors:  Varaprasad Kolla; Paul Jenö; Suzette Moes; Sevgi Tercanli; Olav Lapaire; Mahesh Choolani; Sinuhe Hahn
Journal:  J Biomed Biotechnol       Date:  2009-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.